Entest BioMedical

Immuno-Therapeutic Cancer Vaccine for Canines (Dog Cancer Vaccine)

The first area of focus involves the development of an immuno-therapeutic cancer vaccine for canines. One in every four dogs will develop some sort of cancer during its lifetime. The Company’s goal in this area is to create a treatment that will jumpstart the dog’s own immune system to fight cancer, and we have a device that is in development that we believe will be a “game-changer” for canine oncology. With the rollout of our “canines first” approach, Entest feels it can penetrate the veterinary market in the very near term (one to three years) and eventually take this immuno-therapeutic cancer vaccine into human trials once enough paid animal cases support our vaccine’s efficacy.

Stem Cell Therapy for Chronic Obstructive Pulmonary Disease (COPD) in Humans

The second area of interest for Entest is the development of a stem cell therapy that incorporates “homing” stimulator technology for the treatment of Chronic Obstructive Pulmonary Disease (COPD). COPD is the 4th leading cause of death in the United States. There is currently no cure for COPD, only treatments that provide temporary relief of symptoms. Entest believes that stem cell therapy coupled with a “homing” stimulator will direct stem cells to diseased lung tissue. Entest believes this approach could cause damaged tissue to regenerate. Entest sees applications for this treatment in both veterinary and human venues.